Post-finasteride syndrome

"Post-finasteride syndrome" (PFS) is the name patients and some researchers give to sexual, mental and physical symptoms that reportedly start on finasteride (or dutasteride) and persist for months or years after stopping. Whether it is a distinct drug-caused disease, a rare individual reaction, a nocebo or psychiatric phenomenon, or some mix is still unresolved in October 2026. This page lays out both sides.

Key takeaways

• During treatment, finasteride 1 mg modestly raises sexual side effects over placebo (label: erectile dysfunction 1.3% vs 0.7%, decreased libido 1.8% vs 1.3% in year 1; meta-analysis relative risk 1.66). That part is settled. Propecia label; Lee 2019
• Persistence after stopping is acknowledged by regulators as reported: the US label lists sexual dysfunction that continued after stopping, the MHRA says it has persisted in some patients after they stopped, and the EMA confirmed suicidal ideation as a side effect of finasteride tablets in May 2025. Propecia label; MHRA 2024; EMA 2025
• How often it happens is unknown. The EMA says the frequency of suicidal ideation cannot be estimated; its review counted 313 EudraVigilance cases for finasteride against about 270 million patient-years of use. EMA 2025
• The best controlled data are reassuring but imperfect. Long-term follow-up of the 18,880-man Prostate Cancer Prevention Trial found no excess of 22 PFS-type conditions over 267,983 person-years, but those men were 55 or older and took 5 mg. Till 2026
• Nocebo and reporting bias are real and large. Telling men about sexual side effects roughly tripled reported sexual problems in a blinded trial (43.6% vs 15.3%), and reports to US and WHO safety databases jumped after 2012, when patient advocacy grew. Mondaini 2007; Nguyen 2021; Gupta 2025; Gupta 2026
• But nocebo does not explain every signal. In a US claims database, men who stopped finasteride 1 mg had more new sexual-dysfunction diagnoses than omeprazole users (hazard ratio 1.62). In one US health system, longer finasteride exposure in men aged 16 to 42 predicted erectile dysfunction persisting after stopping (0.8% of 4,284 men). Guo 2016; Kiguradze 2017
• Regulators diverge. The EMA kept finasteride on the market with a patient card, while Belgian and French members dissented and called the benefit-risk for hair loss negative. EMA 2025; CMDh 2025
• The likely picture: most men tolerate finasteride, sexual side effects during use are uncommon and usually reversible, nocebo inflates them, and a small, unquantified number of men report severe persistent symptoms that are not yet explained. Mood changes on the 1 mg tablet are a reason to stop and seek help.

What is claimed

• The core reported cluster is persistent low libido, erectile dysfunction, reduced arousal, orgasm problems, depression, anxiety and cognitive complaints. In 71 men interviewed in 2011, 94% reported low libido and 92% erectile dysfunction, lasting a mean of 40 months after stopping. Irwig 2011
• Among 61 former users with persistent sexual symptoms, 75% had depressive symptoms and 44% had suicidal thoughts, vs 10% and 3% of 29 controls. Irwig 2012
• An online survey of 131 men (mean age 24) found persistent symptoms in physical, sexual, cognitive and psychological domains. Ganzer 2015
• Weakness of this evidence: these men were self-selected from patient networks, with recall bias and no baseline data, and the authors list selection and recall bias themselves. Irwig 2011

Evidence for a real drug effect

• Claims and medical-record cohorts: hazard ratio 1.62 for persistent sexual dysfunction vs omeprazole users (1,390 men stopping finasteride 1 mg) Guo 2016; persistent erectile dysfunction in 1.4% of 11,909 exposed men, with longer exposure the strongest predictor in young men. Kiguradze 2017
• French pharmacovigilance: 40 cases of depression or suicidality without sexual dysfunction in men on 1 mg for hair loss (median age 31); 40% involved suicidality and two had a positive rechallenge. Geniaux 2026
• Biological findings in small samples: altered neurosteroid levels in cerebrospinal fluid (3 patients vs 5 controls Melcangi 2013; 16 patients Melcangi 2017); more frequent methylation of the SRD5A2 gene promoter in cerebrospinal fluid (56.3% vs 7.7%) Melcangi 2019; higher androgen receptor expression in penile skin (26 patients vs 26 controls). Howell 2021 These are small case-control studies and cannot show the drug caused the differences.
• Signals in drug-safety databases: a WHO database showed a suicidality reporting odds ratio of 1.63 overall, higher in men under 45 and in alopecia users Nguyen 2021; a 2025 analysis found a much stronger signal for finasteride (odds ratio 7.28) than dutasteride Lee 2025; updated US data again showed more psychiatric and libido reports for finasteride, mainly in young men on low doses. Chiappini 2026
• Critics' view: a 2025 review argues the evidence shows finasteride can cause depression and suicidality and that regulators were two decades late. Brezis 2025

Evidence against, or for other explanations

• Randomised data: in the Prostate Cancer Prevention Trial (17,313 men analysed), finasteride raised sexual-dysfunction scores only slightly, and the difference shrank over 7 years Moinpour 2007; in the 20-year follow-up none of 22 PFS-type conditions differed between finasteride and placebo. Till 2026
• Hormones look normal in affected men: a detailed hormonal, genetic and brain-imaging workup of men with persistent symptoms found no androgen deficiency, no reduced androgen action and no persistent 5-alpha-reductase inhibition; the men did show depressed mood and brain-imaging patterns like depression. Basaria 2016
• Stimulated reporting: US safety-database reports showed no suicidality signal for finasteride in 2006 to 2011 but signals in 2013 to 2018 and 2019 to 2023 Gupta 2025, and sexual reports climbed after 2012, the year patient-advocacy awareness grew. Dutasteride, which suppresses DHT more, produces fewer reports, which fits reporting bias better than pharmacology. Gupta 2026; Lee 2025
• Depression risk depends on the comparison group: a 2026 meta-analysis of 5 cohorts (2.5 million men) found a hazard ratio of 1.61 vs non-users but 0.89 vs men taking alpha-blockers for the same prostate condition, implying most of the apparent risk reflects the underlying illness. Nguyen 2026 See also null active-comparator studies. Hagberg 2017; Dyson 2020 These were mostly older men with enlarged prostates, not young hair-loss users.
• Large cohorts find no suicide increase: Ontario suicide hazard ratio 0.88 Welk 2017; Sweden, suicide not associated Garcia-Argibay 2022; UK Biobank and genetic analysis, no association. Wang 2025
• Psychogenic hypothesis: one trichologist argues PFS may be a somatic delusional disorder with potential for mass psychogenic illness. Trueb 2019 Of 54 Spanish hair specialists, 83.3% had never seen a case and 98.1% thought it psychiatric in origin. Moreno-Arrones 2026 That is expert opinion, not data.
• Pre-existing vulnerability: the French cases had a psychiatric history in only 22.5% Geniaux 2026, though the Spanish specialists identified young men with prior anxiety or depression as a risk profile. Moreno-Arrones 2026

Recent reviews (2025 to 2026)

• A 2025 urology review concludes that some men could develop a plethora of non-neglectable physical and psychological symptoms and calls for multidisciplinary research. Cilio 2025
• A 2025 review describes three 5-alpha-reductase types, notes that 5-ARIs cross the blood-brain barrier, and proposes neurosteroid disruption as a mechanism. Leliefeld 2025
• A 2026 study of 129 symptomatic former users found erectile function did not improve over 6 months, while depression and anxiety scores fell without normalising; more cumulative exposure and older age predicted worse scores. Jedrzejczyk 2026

Regulators: timeline

What it means for your hair

PFS risk does not depend on curl pattern, thickness, density or porosity. What the evidence suggests matters instead:

• Age and indication: signals cluster in men under 45 using 1 mg for hair loss. Nguyen 2021; Lee 2025
• Mental-health history: regulators ask prescribers to check for prior depression or suicidal ideation before prescribing. MHRA 2024
• Route: topical finasteride produces fewer post-finasteride-type reports in US safety data, and the EMA found no suicidality link for the spray, but the FDA has received persistent-symptom reports for compounded topicals. Gupta 2026; EMA 2025; FDA 2025

Myths and facts

• Myth: "Finasteride side effects are a myth invented online." Fact: sexual side effects during treatment are shown in meta-analyses of trials, and three major regulators now warn about mood effects and persistence. Lee 2019; EMA 2025
• Myth: "Finasteride commonly causes permanent impotence." Fact: in trials the excess risk of erectile dysfunction during treatment is about 1 in 80 Mella 2010, and persistent cases are rare enough that no controlled study has measured their frequency.
• Myth: "PFS proves finasteride wrecks testosterone." Fact: men with persistent symptoms had normal testosterone and DHT levels when tested. Basaria 2016
• Myth: "Reading about side effects can't cause them." Fact: being told about sexual side effects roughly tripled reports in a blinded trial. Mondaini 2007

Bottom line

Finasteride is effective, and its sexual side effects are uncommon and usually reversible, but neither "totally safe" nor "dangerous drug" fits the evidence. The official advice is that if you take the 1 mg tablet and your mood drops or you have suicidal thoughts, you should stop and contact a doctor immediately. MHRA 2024; EMA 2025 If you have current or past depression, anxiety or suicidal thoughts, talk to a doctor before taking oral finasteride, and consider non-hormonal options such as minoxidil first. The frequency of persistent symptoms is unknown, and the strongest controlled study found no excess in older men, so the evidence in young men is weaker. Topical finasteride lowers blood levels and has fewer reports, but it is not proven risk-free. Dose changes or tapering are a conversation to have with a prescriber. Discuss with a doctor.